Investor mix
4 investors on record; lead investors include Newpath Partners, Hatteras Venture Partners.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 100% |
Developer of messenger ribonucleic acid therapies for immune cell programming
4 investors on record; lead investors include Newpath Partners, Hatteras Venture Partners.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 100% |